Clinical Perspectives of Statin-Induced Rhabdomyolysis

American Journal of Medicine

Volumn 119, Issue 5, 2006, Pages 400-409

  Antons, Kenneth A ^a   Williams, Craig D ^b   Baker, Steven K ^c   Phillips, Paul S ^a  

^a SCRIPPS MERCY HOSPITAL   (United States)

^b PURDUE UNIVERSITY   (United States)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; UBIDECARENONE;

ALKALINITY; ARTICLE; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DIAGNOSTIC APPROACH ROUTE; DRUG TOLERABILITY; FLUID THERAPY; HEART FUNCTION TEST; HUMAN; HYPERLIPIDEMIA; LABORATORY TEST; MEDICAL EXAMINATION; MUSCLE BIOPSY; MYALGIA; MYOPATHY; MYOSITIS; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK FACTOR; ASIAN; CHEMICALLY INDUCED DISORDER; EXERCISE; PATHOLOGY; REVIEW;

ASIAN CONTINENTAL ANCESTRY GROUP; EXERCISE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; RHABDOMYOLYSIS; RISK FACTORS;

EID: 33646558252     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.02.007     Document Type: Note

References (117)

1. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. a randomised placebo-controlled trial. Lancet 360 9326 (2002) 7-22
2. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 15 (2004) 1495-1504
3. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA). a multicentre randomised controlled trial. Lancet 361 9364 (2003) 1149-1158
4. Foley K.A., Simpson Jr. R.J., Crouse III J.R., Weiss T.W., Markson L.E., and Alexander C.M. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 92 1 (2003) 79-81
5. O'Meara J.G., Kardia S.L., Armon J.J., Brown C.A., Boerwinkle E., and Turner S.T. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med 28;164 12 (2004) 1313-1318
6. Graham D.J., Staffa J.A., Shatin D., et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292 21 (2004) 2585-2590
7. Staffa J.A., Chang J., and Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346 7 (2002) 539-540
8. Poels P.J., and Gabreels F.J. Rhabdomyolysis. a review of the literature. Clin Neurol Neurosurg 95 3 (1993) 175-192
9. Lofberg M., Jankala H., Paetau A., Harkonen M., and Somer H. Metabolic causes of recurrent rhabdomyolysis. Acta Neurol Scand 98 4 (1998) 268-275
10. Gabow P.A., Kaehny W.D., and Kelleher S.P. The spectrum of rhabdomyolysis. Medicine (Baltimore) 61 3 (1982) 141-152
11. Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., Grundy S.M., Cleeman J.I., and Lenfant C. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke 33 9 (2002) 2337-2341
12. Gaist D., Rodriguez L.A., Huerta C., Hallas J., and Sindrup S.H. Lipid-lowering drugs and risk of myopathy. a population-based follow-up study. Epidemiology 12 5 (2001) 565-569
13. Grundy S.M. The issue of statin safety. where do we stand?. Circulation 111 23 (2005) 3016-3019
14. Abourjaily H.M., sheikh-Ali A.A., and Karas R.H. Comparison of the frequency of adverse events in patients treated with atorvastatin or simvastatin. Am J Cardiol 91 8 (2003) 999-1002 A7
15. Omar M.A., and Wilson J.P. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 36 2 (2002) 288-295
16. Sheikh-Ali A., Ambrose M.S., Kuvin J.T., and Karas R.H. The safety of rosuvastatin as used in common clinical practice. A postmarketing analysis. Circulation 111 23 (2005) 3051-3057
17. Food and Drug Administration advisory meeting briefing document for the use of Crestor (2003) June 11, Report No.: NDA 21-366
18. Kordas K.C., Phillips P.S., and Golomb B.A. Clinical characteristics of 1053 patients with statin associated muscle complaints. [Abstract]. Arterioscler Thromb Vasc Biol 24 (2004) e51-e136
19. Bae J., Jarcho J.A., Denton M.D., and Magee C.C. Statin specific toxicity in organ transplant recipients. case report and review of the literature. J Nephrol 15 3 (2002) 317-319
20. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther 17 3 (2003) 265-285
21. Diekman T., Lansberg P.J., Kastelein J.J., and Wiersinga W.M. Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. Arch Intern Med 155 14 (1995) 1490-1495
22. Gascon R.G., Bertomeu B.F., Meneu M.V., and Fenollosa T. [Unnoticed hypothyroidism and myopathy due to lipid-lowering drugs]. Aten Primaria 27 6 (2001) 442-443
23. Grundy S.M. Statin therapy in older persons. pertinent issues. Arch Intern Med 162 12 (2002) 1329-1331
24. Maxa J.L., Melton L.B., Ogu C.C., Sills M.N., and Limanni A. Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole. Ann Pharmacother 36 5 (2002) 820-823
25. Ness G.C., and Chambers C.M. Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase. the concept of cholesterol buffering capacity. Proc Soc Exp Biol Med 224 1 (2000) 8-19
26. O'Neil-Callahan K., Katsimaglis G., Tepper M.R., et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery. the Statins for Risk Reduction in Surgery (StaRRS) study. J Am Coll Cardiol 45 3 (2005) 336-342
27. Pia I.G., Garrido Sanjuan J.A., Gonzalez G.C., and Sesma S.P. [Antilipemic agents, hypothyroidism, and rhabdomyolysis]. Rev Clin Esp 200 4 (2000) 236-237
28. Wilhelmi M., Winterhalter M., Fischer S., et al. Massive postoperative rhabdomyolysis following combined CABG/abdominal aortic replacement. a possible association with HMG-CoA reductase inhibitors. Cardiovasc Drugs Ther 16 5 (2002) 471-475
29. Sinzinger H., Wolfram R., and Peskar B.A. Muscular side effects of statins. J Cardiovasc Pharmacol 40 2 (2002) 163-171
30. Thompson P.D., Zmuda J.M., Domalik L.J., Zimet R.J., Staggers J., and Guyton J.R. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 46 10 (1997) 1206-1210
31. Unnikrishnan D., and Satish B. Exertion-induced rhabdomyolysis in a patient on statin therapy. Nephrol Dial Transplant 20 1 (2005) 244
32. Department of Health and Human Services. Response to Sidney Wolff Dated 3/11/05. Available at: http://www.fda.gov/cder/drug/infopage/rosuvastatin/crestor_CP.pdf. Accessed March 11, 2005
33. Food and Drug Administration Center for Drug Evaluation and Research. FDA Public Health Advisory on Crestor (rosuvastatin) Available at: http://www.fda.gov/cder/drug/advisory/crestor_3_2005.htm. Accessed March 2, 2005
34. Forestier F., Breton Y., Bonnet E., and Janvier G. Severe rhabdomyolysis after laparoscopic surgery for adenocarcinoma of the rectum in two patients treated with statins. Anesthesiology 97 4 (2002) 1019-1021
35. Pan W., Pintar T., Anton J., Lee V.V., Vaughn W.K., and Collard C.D. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 110 11 Suppl 1 (2004) II45-II49
36. Durazzo A.E., Machado F.S., Ikeoka D.T., et al. Reduction in cardiovascular events after vascular surgery with atorvastatin. a randomized trial. J Vasc Surg 39 5 (2004) 967-975
37. Ali I.S., and Buth K.J. Preoperative statin use and in-hospital outcomes following heart surgery in patients with unstable angina. Eur J Cardiothorac Surg 27 6 (2005) 1051-1056
38. Ballantyne C.M., Corsini A., Davidson M.H., et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163 5 (2003) 553-564
39. Omar M.A., Wilson J.P., and Cox T.S. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 35 9 (2001) 1096-1107
40. Jacobson R.H., Wang P., and Glueck C.J. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. JAMA 277 4 (1997) 296-297
41. Schmassmann-Suhijar D., Bullingham R., Gasser R., Schmutz J., and Haefeli W.E. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 351 9120 (1998) 1929-1930
42. Bogman K., Peyer A.K., Torok M., Kusters E., and Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 132 6 (2001) 1183-1192
43. Chang J.T., Staffa J.A., Parks M., and Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 13 7 (2004) 417-426
44. Igel M., Sudhop T., and vonBergmann K. Metabolism and Drug Interactions of 3-hydroxy-3methylglutaryl Coenzyme A-reductase inhibitors (Statins). Eur J Clin Pharmacol 57 (2001) 357-364
45. Lee E., Ryan S., Birmingham B., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78 4 (2005) 330-341
46. Backman J.T., Kyrklund C., Kivisto K.T., Wang J.S., and Neuvonen P.J. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clinical Pharmacology & Therapeutics 68 2 (2000) 122-129 August
47. Bergman A.J., Murphy G., Burke J., et al. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 44 9 (2004) 1054-1062
48. Ireland J.H., Eggert C.H., Arendt C.J., and Williams A.W. Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate. Ann Intern Med 142 11 (2005) 949-950
49. Jacob S.S., Jacob S., Williams C., and Deeg M.A. Simvastatin, fenofibrate, and rhabdomyolysis. Diabetes Care 28 5 (2005) 1258
50. Kantola T., Kivisto K.T., and Neuvonen P.J. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 64 2 (1998) 177-182
51. Martin P.D., Dane A.L., Schneck D.W., and Warwick M.J. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clinical Therapeutics 25 2 (2003) 459-471
52. Pentikainen P.J., Saraheimo M., Schwartz J.I., et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 32 2 (1992) 136-140
53. Vladutiu R, Isackson P, Peltier W, et al. Genetic risk factors and metabolic abnormalities associated with lipid lowering therapies. Muscle Nerve. In press.
54. Phillips P.S., Ciaraldi T.P., Kim D.L., Verity M.A., Wolfen A.R., and Henry R.R. Myotoxic reactions to lipid-lowering therapy are associated with altered oxidation of fatty acids. [abstract]. J Am Coll Cardiol 45 (2005) 413A
55. Phillips P.S., Phillips C.T., Sullivan M.J., Naviaux R.K., Haas R.H., and Scripps Mercy Research Center. Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis. 177 1 (2004) 183-188
56. Phillips P.S., Gray N.L., McDonald F.G., Blaszcak M., Wolfson T., and Sullivan M.J. Colesevelam HCL is safe and effective in patients with statin myotoxicity. Atheroscler Thromb Vasc Biol Online Journal 25 (2005) e97
57. Bardosi A., and Dickman U. Necrotizing myopathy with paracrystalline inclusion bodies in hypervitaminosis E. Acta Neuropathol 75 (1987) 166-172
58. Lima A.F., Evangelista T., and de C.M. Increased creatine kinase and spontaneous activity on electromyography, in amyotrophic lateral sclerosis. Electromyogr Clin Neurophysiol 43 3 (2003) 189-192
59. Streichenberger N., Meyronet D., Fiere V., Pellissier J.F., and Petiot P. Focal myositis associated with S-1 radiculopathy. report of two cases. Muscle Nerve 29 3 (2004) 443-446
60. Koumis T., Nathan J.P., Rosenberg J.M., and Cicero L.A. Strategies for the prevention and treatment of statin-induced myopathy. is there a role for ubiquinone supplementation?. Am J Health Syst Pharm 61 5 (2004) 515-519
61. Bargossi A.M., Battino M., Gaddi A., et al. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Int J Clin Lab Res 24 3 (1994) 171-176
62. Musumeci O., Naini A., Slonim A.E., et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology 56 7 (2001) 849-855
63. Thibault A., Samid D., Tompkins A.C., et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2 3 (1996) 483-491
64. Artuch R., Colome C., Vilaseca M.A., Pineda M., and Campistol J. [Ubiquinone: metabolism and functions. Ubiquinone deficiency and its implication in mitochondrial encephalopathies. Treatment with ubiquinone]. Rev Neurol 29 1 (1999) 59-63
65. Van M.L., Trijbels F., DiMauro S., et al. Coenzyme Q-responsive Leigh's encephalopathy in two sisters. Ann Neurol 52 6 (2002) 750-754
66. Lees R.S., and Lees A.M. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 333 10 (1995) 664-665
67. Walravens P.A., Greene C., and Frerman F.E. Lovastatin, isoprenes, and myopathy. Lancet 2 8671 (1989) 1097-1098
68. Chariot P., Abadia R., Agnus D., Danan C., Charpentier C., and Gherardi R.K. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome. Am J Med 94 1 (1993) 109-110
69. Kim W.S., Kim M.M., Choi H.J., et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 19 1 (2001) 81-83
70. Kelly P., Vasu S., Gelato M., McNurain M., and Lawson W. Coenzyme Q10 improves myopathic pain in statin treated patients. [abstract]. J Am Coll Cardiol 45 (2005) 3A
71. Shults C.W., Oakes D., Kieburtz K., et al. Effects of coenzyme Q10 in early Parkinson disease. evidence of slowing of the functional decline. Arch Neurol 59 10 (2002) 1541-1550
72. Molyneux S., Florkowski C., Lever M., and George P. The bioavailability of coenzyme Q10 supplements available in New Zealand differs markedly. N Z Med J 117 1203 (2004) U1108
73. Sochman J., and Podzimkova M. Not all statins are alike. induced rhabdomyolysis on changing from one statin to another one. Int J Cardiol 99 1 (2005) 145-146
74. Ucar M., Mjorndal T., and Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 22 6 (2000) 441-457
75. Golomb B.A. Implications of statin adverse effects in the elderly. Expert Opin Drug Saf 4 3 (2005) 389-397
76. Golomb B.A., Yang E., Denenberg J., and Criqui M.H. Statin-associated adverse effects. Circulation 107 (2003) e7028-e7029 Presented at the 43rd Annual Conference on Cardiovascular Disease Epidemiology and Prevention. Miami, FL. March 7, 2003
77. Pitt B. Low-density lipoprotein cholesterol in patients with stable coronary heart disease-is it time to shift our goals?. N Engl J Med 352 14 (2005) 1483-1484
78. Davidson M.H., Maccubbin D., Stepanavage M., Strony J., and Musliner T. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 97 2 (2006) 223-228
79. Fux R., Morike K., Gundel U.F., Hartmann R., and Gleiter C.H. Ezetimibe and statin-associated myopathy. Ann Intern Med 140 8 (2004) 671-672
80. Phillips P.S. Ezetimibe and statin-associated myopathy. Ann Intern Med 141 8 (2004) 649
81. Havranek J.M., Wolfsen A.R., Warnke G.A., and Phillips P.S. Monotherapy with ezetimibe causing myopathy. Am J Med 119 (2006) 285-286
82. Perez-Calvo J., Civeira-Murillo F., and Cabello A. Worsening myopathy associated with ezetimibe in a patient with McArdle disease. QJM 98 6 (2005) 461-462
83. Magarian G.J., Lucas L.M., and Colley C. Gemfibrozil-induced myopathy. Arch Intern Med 151 9 (1991) 1873-1874
84. Langer T., and Levy R.I. Acute muscular syndrome associated with administration of clofibrate. N Engl J Med 279 16 (1968) 856-858
85. Litin S.C., and Anderson C.F. Nicotinic acid-associated myopathy. a report of three cases. Am J Med 86 4 (1989) 481-483
86. Barker B.J., Goodenough R.R., and Falko J.M. Fenofibrate monotherapy induced rhabdomyolysis. Diabetes Care 26 8 (2003) 2482-2483
87. Jones P.H., and Davidson M.H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 95 1 (2005) 120-122
88. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 25 (2002) 3143-3421
89. Drown D.J. The Portfolio Diet to reduce the risk of heart disease. Prog Cardiovasc Nurs 19 2 (2004) 73
90. Jenkins D.J., Kendall C.W., Marchie A., et al. Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am J Clin Nutr 81 2 (2005) 380-387
91. Davidson M.H., Dillon M.A., Gordon B., et al. Colesevelam hydrochloride (cholestagel). a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 159 16 (1999) 1893-1900
92. Phillips P.S., Haas R.H., and Barshop B. Utility of abnormal 3-methylgluaconic aciduria (3MGA) in diagnosing statin associated myopathy. Atheroscler Thromb Vasc Biol Online Journal. 22 (2002) 878
93. Simpson J.A., Labugger R., Hesketh G.G., et al. Differential detection of skeletal troponin I isoforms in serum of a patient with rhabdomyolysis. markers of muscle injury?. Clin Chem 48 7 (2002) 1112-1114
94. Vockley J., Singh R.H., and Whiteman D.A. Diagnosis and management of defects of mitochondrial beta-oxidation. Curr Opin Clin Nutr Metab Care 5 6 (2002) 601-609
95. Fosslien E. Review. mitochondrial medicine-cardiomyopathy caused by defective oxidative phosphorylation. Ann Clin Lab Sci 33 4 (2003) 371-395
96. Madsen L., Rustan A.C., Vaagenes H., Berge K., Dyroy E., and Berge R.K. Eicosapentaenoic and docosahexaenoic acid affect mitochondrial and peroxisomal fatty acid oxidation in relation to substrate preference. Lipids 34 9 (1999) 951-963
97. Padma V.V., and Devi C.S. Effect of fish oil on mitochondrial respiration in isoproterenol induced myocardial infarction in rats. Indian J Exp Biol 40 3 (2002) 268-272
98. Infante J.P., and Huszagh V.A. Secondary carnitine deficiency and impaired docosahexaenoic (22:6n-3) acid synthesis: a common denominator in the pathophysiology of diseases of oxidative phosphorylation and beta-oxidation. FEBS Lett 468 1 (2000) 1-5
99. Halvorsen B., Rustan A.C., Madsen L., et al. Effects of long-chain monounsaturated and n-3 fatty acids on fatty acid oxidation and lipid composition in rats. Ann Nutr Metab 45 1 (2001) 30-37
100. Popjak G., Boehm G., Parker T.S., Edmond J., Edwards P.A., and Fogelman A.M. Determination of mevalonate in blood plasma in man and rat. Mevalonate "tolerance" tests in man. J Lipid Res 20 6 (1979) 716-728
101. Bhuiyan J., and Seccombe D.W. The effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibition on tissue levels of carnitine and carnitine acyltransferase activity in the rabbit. Lipids 31 (1996) 867-870
102. Westwood F.R., Bigley A., Randall K., Marsden A.M., and Scott R.C. Statin-induced muscle necrosis in the rat. distribution, development, and fibre selectivity. Toxicol Pathol 33 (2005) 246-257
103. Bifulco M., Laezza C., Aloj S.M., and Garbi C. Mevalonate controls cytoskeleton organization and cell morphology in thyroid epithelial cells. J Cell Physiol 155 2 (1993) 340-348
104. Flint O.P., Masters B.A., Gregg R.E., and Durham S.K. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 145 1 (1997) 91-98
105. Sacher J., Weigl L., Werner M., Szegedi C., and Hohenegger M. Delineation of myotoxicity induced by HMG-CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther 24 (2005) jpet
106. Johnson T.E., Zhang X., Bleicher K.B., et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol 200 3 (2004) 237-250
107. O'Donnell M.P., Kasiske B.L., Kim Y., Atluru D., and Keane W.F. Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 91 1 (1993) 83-87
108. Kim R., Rine J., and Kim S.H. Prenylation of mammalian Ras protein in Xenopus oocytes. Mol Cell Biol 10 11 (1990) 5945-5949
109. Soma M.R., Corsini A., and Paoletti R. Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. Toxicol Lett. 1-15 (1992) 64-65
110. Nakahara K., Kuriyama M., and Yoshidome H. Myopathy induced by HMG-CoA reductase inhibitors in rabbits. a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol 152 (1998) 99-106
111. Waclawik A.J., Lindal S., and Engel A.G. Experimental lovastatin myopathy. J Neuropath Exp Neurol ?? (1993) 542-549
112. Schaefer W.H., Lawrence J.W., Loughlin A.F., et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 194 1 (2004) 10-23
113. Westwood F.R., Bigley A., Randall K., Marsden A.M., and Scott R.C. Statin-induced muscle necrosis in the rat. distribution, development, and fibre selectivity. Toxicol Pathol 33 2 (2005) 246-257
114. Paiva H., Thelen K.M., Van C.R., et al. High-dose statins and skeletal muscle metabolism in humans. a randomized, controlled trial. Clin Pharmacol Ther 78 1 (2005) 60-68
115. Flint O.P., Masters B.A., Gregg R.E., and Durham S.K. HMG CoA reductase inhibitor-induced myotoxicity. pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture. Toxicol Appl Pharmacol 145 1 (1997) 99-110
116. Urso M.L., Clarkson P.M., Hittel D., Hoffman E.P., and Thompson P.D. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol 25 (2005) 2560-2566
117. Salarieh A., Soler A.P., and Axiotis C.A. Overexpression of neural cell adhesion molecule in regenerative muscle fibers in 3-hydroxy-3-methylglutaryl coenzyme. a reductase inhibitor-induced rhabdomyolysis. Appl Immunohistochem Mol Morphol 12 3 (2004) 234-239